<DOC>
	<DOCNO>NCT00601159</DOCNO>
	<brief_summary>Primary objective study evaluate efficacy gemcitabine cisplatin first line therapy patient triple-negative MBC . 80 patient treat study .</brief_summary>
	<brief_title>Gemcitabine Cisplatin First Line Combination Therapy Patients With Triple-negative MBC</brief_title>
	<detailed_description>Triple-negative breast tumor could contribute poor prognosis compare luminal A breast cancer.Fewer study reveal Cisplatin-based therapy may effective type breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Give write informed consent prior study , understand patient right withdraw study time without prejudice Be female ≥18 ≤75 year age Be ambulatory ECOG performance stastus ≤1 Have histological confirm breast cancer , speciman confirm ER negative , PR negatiev , HER2 negative immunochemistry technich Fudan cancer hospital . Locally advanced metastastic breast cancer n't receive firstline chemotherapy . No matter whether patient receive anthracyclin taxane treatment neoadjuvant adjuvant treatment . Have least one target lesion accord RECIST criterion . Exclusion criterion : Preganant lactate woman Advaced patient receive one chemotherapy Chemotherapy within four week precede treatment start ECOG ≥ 2 Radiotherapy axial skeleton within 4 week precede study treatment start insufficient recovery effect prior radiotherapy Participation investigational drug study within 4 week preceeding treatment start Evidence CNS metastasis History another malignacy within last five year except cure basal cell carcinoma skin carcinoma insitu uterine cervix contralateral breast cancer Abnormal laboratory value : hemoglobin &lt; 8 . 0g/dl , neutrophil &lt; 1.5×109/L , platelet &lt; 100×109/L . serum creatine &gt; upper limit normal ( ULN ) serum bilirubin &gt; ULN ALT AST &gt; 5×ULN AKP &gt; 5×ULN Serious uncontrolled intercurrence infection Life expectancy le 3 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>triple-negative Breast Cancer</keyword>
	<keyword>cisplatin</keyword>
	<keyword>chemotherapy</keyword>
</DOC>